{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:12:20Z","timestamp":1791922340559,"version":"4.3.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40121-023-00888-w","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T08:02:32Z","timestamp":1701676952000},"page":"2649-2663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Meningococcal Disease in the Post\u2013COVID-19 Era: A Time to Prepare"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-3345","authenticated-orcid":false,"given":"David E.","family":"Bloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-3744","authenticated-orcid":false,"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7562-7228","authenticated-orcid":false,"given":"Peter C.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-9446","authenticated-orcid":false,"given":"Marco A. P.","family":"Safadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-7592","authenticated-orcid":false,"given":"Apostolos","family":"Charos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0975-4154","authenticated-orcid":false,"given":"Katharina","family":"Schley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-4043","authenticated-orcid":false,"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11910-015-0524-6","volume":"15","author":"R Dwilow","year":"2015","unstructured":"Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century\u2014an update for the clinician. Curr Neurol Neurosci Rep. 2015;15:2.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(06)67932-4","volume":"367","author":"MJ Thompson","year":"2006","unstructured":"Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397\u2013403.","journal-title":"Lancet"},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","volume":"37","author":"B Wang","year":"2019","unstructured":"Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37:2768\u201382.","journal-title":"Vaccine"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, Muller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421\u201338.","journal-title":"Infect Dis Ther"},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","volume":"18","author":"R Acevedo","year":"2019","unstructured":"Acevedo R, Bai X, Borrow R, et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18:15\u201330.","journal-title":"Expert Rev Vaccines"},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s40121-021-00499-3","volume":"10","author":"L Soumahoro","year":"2021","unstructured":"Soumahoro L, Abitbol V, Vicic N, Bekkat-Berkani R, Safadi MAP. Meningococcal disease outbreaks: a moving target and a case for routine preventative vaccination. Infect Dis Ther. 2021;10:1949\u201388.","journal-title":"Infect Dis Ther"},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/501371","volume":"193","author":"LH Harrison","year":"2006","unstructured":"Harrison LH, Jolley KA, Shutt KA, et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis. 2006;193:1266\u201374.","journal-title":"J Infect Dis"},{"key":"888_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1073\/pnas.94.1.271","volume":"94","author":"JS Swartley","year":"1997","unstructured":"Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA. 1997;94:271\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/microorganisms9030519","volume":"9","author":"YL Tzeng","year":"2021","unstructured":"Tzeng YL, Stephens DS. A narrative review of the W, X, Y, E, and NG of meningococcal disease: emerging capsular groups, pathotypes, and global control. Microorganisms. 2021;9:519.","journal-title":"Microorganisms"},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","volume":"20","author":"E Miller","year":"2001","unstructured":"Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20:S58\u201367.","journal-title":"Vaccine"},{"key":"888_CR11","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S2468-2667(17)30157-3","volume":"2","author":"MJ Knol","year":"2017","unstructured":"Knol MJ, Hahne SJM, Lucidarme J, et al. Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study. Lancet Public Health. 2017;2:e473\u201382.","journal-title":"Lancet Public Health"},{"key":"888_CR12","doi-asserted-by":"crossref","unstructured":"World Health Organization. Defeating meningitis by 2030: a global road map. Jun 24, 2021. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240026407. Accessed 21 Dec 2022.","DOI":"10.1016\/S1473-3099(21)00712-X"},{"key":"888_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483\u201398.","journal-title":"J Infect"},{"key":"888_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/21645515.2018.1528831","volume":"15","author":"C Burman","year":"2019","unstructured":"Burman C, Serra L, Nuttens C, et al. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccin Immunother. 2019;15:459\u201369.","journal-title":"Hum Vaccin Immunother"},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martinon-Torres","year":"2022","unstructured":"Martinon-Torres F, Taha MK, Knuf M, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116:85\u201398.","journal-title":"Pathog Glob Health"},{"key":"888_CR16","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S2589-7500(21)00077-7","volume":"3","author":"AB Brueggemann","year":"2021","unstructured":"Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health. 2021;3:e360\u201370.","journal-title":"Lancet Digit Health"},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.idnow.2021.05.004","volume":"51","author":"R Cohen","year":"2021","unstructured":"Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51:418\u201323.","journal-title":"Infect Dis Now"},{"key":"888_CR18","unstructured":"UNICEF. COVID-19 pandemic leads to major backsliding on childhood vaccinations, new WHO, UNICEF data shows. July 15, 2021. Available at: https:\/\/www.unicef.org\/press-releases\/covid-19-pandemic-leads-major-backsliding-childhood-vaccinations-new-who-unicef-data. Accessed 21 Dec 2022."},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jinf.2021.11.016","volume":"84","author":"MR Alderson","year":"2022","unstructured":"Alderson MR, Arkwright PD, Bai X, et al. Surveillance and control of meningococcal disease in the COVID-19 era: a Global Meningococcal Initiative review. J Infect. 2022;84:289\u201396.","journal-title":"J Infect"},{"key":"888_CR20","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3998164","author":"SA Clark","year":"2022","unstructured":"Clark SA, Campbell H, Mensah AA, et al. An increase in group B invasive meningococcal disease among adolescents and young adults in England following easing of COVID-19 containment measures. SSRN Electron J. 2022. https:\/\/doi.org\/10.2139\/ssrn.3998164. (Preprint posted online January 8, 2022).","journal-title":"SSRN Electron J"},{"key":"888_CR21","unstructured":"Sant\u00e9 publique France. [Epidemiological situation of invasive meningococcal infections in France. Update as of December 31, 2022]. Available at: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/situation-epidemiologique-des-infections-invasives-a-meningocoque-en-france.-point-au-31-decembre-2022#:~:text=Avec%2084%20cas%20d'IIM,et%20mars%20selon%20la%20saison. Accessed 1 Mar 2023."},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(20)32007-9","volume":"396","author":"E Han","year":"2020","unstructured":"Han E, Tan MMJ, Turk E, et al. Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe. Lancet. 2020;396:1525\u201334.","journal-title":"Lancet"},{"key":"888_CR23","unstructured":"European Centre for Disease Prevention and Control. Meningococcal disease: recommended vaccinations. Available at: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1. Accessed 21 Dec 2022."},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","volume":"3","author":"KA Jolley","year":"2018","unstructured":"Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124\u20138.","journal-title":"Wellcome Open Res"},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.vaccine.2020.11.067","volume":"39","author":"A Aparecido Nunes","year":"2021","unstructured":"Aparecido Nunes A, De De Jesus Lopes Abreu A, Cintra O, et al. Meningococcal disease epidemiology in Brazil (2005\u20132018) and impact of MenC vaccination. Vaccine. 2021;39:605\u201316.","journal-title":"Vaccine"},{"key":"888_CR26","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1080\/21645515.2021.1996808","volume":"17","author":"MG Gra\u00f1a","year":"2021","unstructured":"Gra\u00f1a MG, Cavada G, Vasquez M, et al. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile. Hum Vaccin Immunother. 2021;17:5603\u201313.","journal-title":"Hum Vaccin Immunother"},{"key":"888_CR27","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1093\/cid\/ciaa1636","volume":"73","author":"M McMillan","year":"2021","unstructured":"McMillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73:e233\u20137.","journal-title":"Clin Infect Dis"},{"key":"888_CR28","unstructured":"Rubis A. Epidemiology of meningococcal disease in the United States. Presented at: Advisory Committee on Immunization Practices Meeting, February 23, 2023; Atlanta, GA, USA."},{"key":"888_CR29","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9vention. Calendrier des vaccinations et recommandations vaccinales 2023. Available at: https:\/\/sante.gouv.fr\/IMG\/pdf\/calendrier_vaccinal_maj-juin23.pdf. Accessed 14 Jun 2023."},{"key":"888_CR30","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Strat\u00e9gie de vaccination pour la pr\u00e9vention des infections invasives \u00e0 m\u00e9ningocoques : Le s\u00e9rogroupe B et la place de BEXSERO\u00ae. Available at: https:\/\/www.has-sante.fr\/jcms\/p_3066921\/fr\/strategie-de-vaccination-pour-la-prevention-des-infections-invasives-a-meningocoques-le-serogroupe-b-et-la-place-de-bexsero#:~:text=Depuis%202013%2C%20l'utilisation%20de,%2C%20%C3%A9pid%C3%A9mie%2C%20hyperend%C3%A9mie%20localis%C3%A9e. Accessed 14 Jun 2023."},{"key":"888_CR31","doi-asserted-by":"publisher","first-page":"111.e1","DOI":"10.1016\/j.cmi.2018.07.014","volume":"25","author":"P Stefanelli","year":"2019","unstructured":"Stefanelli P, Fazio C, Vacca P, et al. An outbreak of severe invasive meningococcal disease due to a capsular switched Neisseria meningitidis hypervirulent strain B:cc11. Clin Microbiol Infect. 2019;25:111.e1\u2013e4.","journal-title":"Clin Microbiol Infect"},{"key":"888_CR32","unstructured":"Outbreak News Today. Meningococcal disease outbreak in S\u00e3o Paulo, Health officials reinforce importance of vaccination. Available at: http:\/\/outbreaknewstoday.com\/meningococcal-disease-outbreak-in-sao-paulo-health-officials-reinforce-importance-of-vaccination-61531\/. Accessed 2 Mar 2023."},{"key":"888_CR33","unstructured":"US Centers for Disease Control and Prevention. Meningococcal disease outbreak among gay, bisexual men in Florida, 2021\u201323. Available at: https:\/\/www.cdc.gov\/meningococcal\/outbreaks\/FL2022.html. Accessed 12 Sep 2023."},{"key":"888_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2021.100955","volume":"13","author":"OC Okonji","year":"2022","unstructured":"Okonji OC, Rackimuthu S, Gangat SA, et al. Meningitis during COVID -19 pandemic in the Democratic Republic of Congo: a call for concern. Clin Epidemiol Glob Health. 2022;13:100955.","journal-title":"Clin Epidemiol Glob Health"},{"key":"888_CR35","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/bmj.320.7238.846","volume":"320","author":"KR Neal","year":"2000","unstructured":"Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ. 2000;320:846\u20139.","journal-title":"BMJ"},{"key":"888_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244716","volume":"16","author":"H Choi","year":"2021","unstructured":"Choi H, Lee HM, Lee W, et al. Longitudinal study of meningococcal carriage rates in university entrants living in a dormitory in South Korea. PLoS ONE. 2021;16:e0244716.","journal-title":"PLoS ONE"},{"key":"888_CR37","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/21645515.2018.1551672","volume":"15","author":"M McMillan","year":"2019","unstructured":"McMillan M, Walters L, Mark T, et al. B Part of It study: a longitudinal study to assess carriage of Neisseria meningitidis in first year university students in South Australia. Hum Vaccin Immunother. 2019;15:987\u201394.","journal-title":"Hum Vaccin Immunother"},{"key":"888_CR38","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820000734","volume":"148","author":"SV Watle","year":"2020","unstructured":"Watle SV, Caugant DA, Tunheim G, et al. Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors. Epidemiol Infect. 2020;148:e80.","journal-title":"Epidemiol Infect"},{"key":"888_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jpeds.2021.11.061","volume":"242","author":"R Cohen","year":"2022","unstructured":"Cohen R, Pettoello-Mantovani M, Somekh E, Levy C. European pediatric societies call for an implementation of regular vaccination programs to contrast the immunity debt associated to coronavirus disease\u20132019 pandemic in children. J Pediatr. 2022;242:260\u20131.e3.","journal-title":"J Pediatr"},{"key":"888_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1473-3099(22)00544-8","volume":"23","author":"MN Billard","year":"2023","unstructured":"Billard MN, Bont LJ. Quantifying the RSV immunity debt following COVID-19: a public health matter. Lancet Infect Dis. 2023;23:3\u20135.","journal-title":"Lancet Infect Dis"},{"key":"888_CR41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.15585\/mmwr.mm6919e2","volume":"69","author":"JM Santoli","year":"2020","unstructured":"Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration\u2014United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:591\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"888_CR42","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1016\/j.vaccine.2022.09.073","volume":"40","author":"CR Chao","year":"2022","unstructured":"Chao CR, Xu L, Cannizzaro N, et al. Trends in HPV vaccine administration and HPV vaccine coverage in children by race\/ethnicity and socioeconomic status during the COVID-19 pandemic in an integrated health care system in California. Vaccine. 2022;40:6575\u201380.","journal-title":"Vaccine"},{"key":"888_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.666848","volume":"9","author":"M Taine","year":"2021","unstructured":"Taine M, Offredo L, Drouin J, et al. Mandatory infant vaccinations in France during the COVID-19 pandemic in 2020. Front Pediatr. 2021;9:666848.","journal-title":"Front Pediatr"},{"key":"888_CR44","unstructured":"GlaxoSmithKline. Half of parents surveyed either cancelled or delayed their child\u2019s scheduled meningitis vaccination during the COVID-19 pandemic \u2013 GSK survey shows. March 21, 2021. Available at: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/half-of-parents-surveyed-either-cancelled-or-delayed-their-child-s-scheduled-meningitis-vaccination-during-the-covid-19-pandemic-gsk-survey-shows-1\/. Accessed 21 Dec 2022."},{"key":"888_CR45","doi-asserted-by":"publisher","first-page":"e2829","DOI":"10.1093\/cid\/ciaa1906","volume":"73","author":"DA Foley","year":"2021","unstructured":"Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin Infect Dis. 2021;73:e2829\u201330.","journal-title":"Clin Infect Dis"},{"key":"888_CR46","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1002\/ppul.25644","volume":"56","author":"C Delestrain","year":"2021","unstructured":"Delestrain C, Danis K, Hau I, et al. Impact of COVID-19 social distancing on viral infection in France: a delayed outbreak of RSV. Pediatr Pulmonol. 2021;56:3669\u201373.","journal-title":"Pediatr Pulmonol"},{"key":"888_CR47","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.15585\/mmwr.mm7029a1","volume":"70","author":"SJ Olsen","year":"2021","unstructured":"Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic\u2014United States, 2020\u20132021. MMWR Morb Mortal Wkly Rep. 2021;70:1013\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"888_CR48","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-052089","volume":"148","author":"R Agha","year":"2021","unstructured":"Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics. 2021;148:e2021052089.","journal-title":"Pediatrics"},{"key":"888_CR49","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3201\/eid2808.220304","volume":"28","author":"M Bertran","year":"2022","unstructured":"Bertran M, Amin-Chowdhury Z, Sheppard CL, et al. Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England. Emerg Infect Dis. 2022;28:1669\u201372.","journal-title":"Emerg Infect Dis"},{"key":"888_CR50","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2352-4642(21)00333-3","volume":"5","author":"L Hatter","year":"2021","unstructured":"Hatter L, Eathorne A, Hills T, Bruce P, Beasley R. Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc Health. 2021;5:e44\u20135.","journal-title":"Lancet Child Adolesc Health"},{"key":"888_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1473-3099(06)70466-2","volume":"6","author":"JF Brundage","year":"2006","unstructured":"Brundage JF. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis. 2006;6:303\u201312.","journal-title":"Lancet Infect Dis"},{"key":"888_CR52","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","volume":"17","author":"CL Trotter","year":"2017","unstructured":"Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data. Lancet Infect Dis. 2017;17:867\u201372.","journal-title":"Lancet Infect Dis"},{"key":"888_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","author":"SJ Gray","year":"2006","unstructured":"Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55:887\u201396.","journal-title":"J Med Microbiol"},{"key":"888_CR54","unstructured":"UK Health Security Agency. Meningococcal disease: laboratory-confirmed cases in England in 2020 to 2021. Available at: https:\/\/www.gov.uk\/government\/publications\/meningococcal-disease-laboratory-confirmed-cases-in-england-in-2020-to-2021. Accessed 12 Sep 2023."},{"key":"888_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14760584.2021.1878030","volume":"20","author":"L Huang","year":"2021","unstructured":"Huang L, Mauskopf J, Farkouh R, Masaquel C. Use of cost-effectiveness analyses for decisions about vaccination programs for meningococcal disease in the United States, United Kingdom, the Netherlands, and Canada. Expert Rev Vaccines. 2021;20:59\u201372.","journal-title":"Expert Rev Vaccines"},{"key":"888_CR56","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v3.27279","author":"S Carroll","year":"2015","unstructured":"Carroll S, Rojas AJ, Glenng\u00e5rd AH, Marin C. Vaccination: short- to long-term benefits from investment. J Mark Access Health Policy. 2015. https:\/\/doi.org\/10.3402\/jmahp.v3.27279.","journal-title":"J Mark Access Health Policy"},{"key":"888_CR57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","volume":"6","author":"H Campbell","year":"2022","unstructured":"Campbell H, Andrews N, Parikh SR, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6:96\u2013105.","journal-title":"Lancet Child Adolesc Health"},{"key":"888_CR58","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/cid\/ciab791","volume":"74","author":"M Ohm","year":"2022","unstructured":"Ohm M, Hahne SJM, van der Ende A, et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2022;74:2173\u201380.","journal-title":"Clin Infect Dis"},{"key":"888_CR59","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.1016\/j.vaccine.2019.09.050","volume":"37","author":"R Villena","year":"2019","unstructured":"Villena R, Valenzuela MT, Bastias M, Santolaya ME. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 2019;37:6915\u201321.","journal-title":"Vaccine"},{"key":"888_CR60","unstructured":"Instituto de Salud Publica (Chile). Informe de Resultados de Vigilancia de Laboratorio: Enfermedad Invasora Neisseria meningitidis 2020. Available at: https:\/\/www.ispch.cl\/wp-content\/uploads\/2021\/02\/Informe-Neisseria-meningitidis-SE-1-53-2020-v1-1.pdf. Accessed 20 May 2022."},{"key":"888_CR61","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.vaccine.2021.02.049","volume":"39","author":"IB Nwogu","year":"2021","unstructured":"Nwogu IB, Jones M, Langley T. Economic evaluation of meningococcal serogroup B (MenB) vaccines: a systematic review. Vaccine. 2021;39:2201\u201313.","journal-title":"Vaccine"},{"key":"888_CR62","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","volume":"21","author":"H Christensen","year":"2020","unstructured":"Christensen H, Al-Janabi H, Levy P, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21:297\u2013309.","journal-title":"Eur J Health Econ"},{"key":"888_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.idnow.2021.05.001","volume":"51","author":"C Gras-Le Guen","year":"2021","unstructured":"Gras-Le Guen C, Vignier N, Kochert F, et al. Why should the meningococcal B vaccine be recommended, and therefore reimbursed, for infants in France? Infect Dis Now. 2021;51:407\u20139.","journal-title":"Infect Dis Now"},{"key":"888_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fpubh.2020.00261","volume":"8","author":"A Stawasz","year":"2020","unstructured":"Stawasz A, Huang L, Kirby P, Bloom D. Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination\u2019s full social and economic benefits. Front Public Health. 2020;8:261.","journal-title":"Front Public Health"},{"key":"888_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91\u2013104.","journal-title":"Value Health"},{"key":"888_CR66","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, et al. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup B invasive meningococcal disease. Infect Dis Ther. 2022;11:367\u201387.","journal-title":"Infect Dis Ther"},{"key":"888_CR67","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","volume":"22","author":"J Shen","year":"2022","unstructured":"Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application\u2014a systematic and clinical review. BMC Public Health. 2022;22:1078.","journal-title":"BMC Public Health"},{"key":"888_CR68","first-page":"1","volume-title":"Hot topics in infection and immunity in children VII. Advances in experimental medicine and biology","author":"DE Bloom","year":"2011","unstructured":"Bloom DE. The value of vaccination. In: Curtis N, Finn A, Pollard AJ, editors. Hot topics in infection and immunity in children VII. Advances in experimental medicine and biology, vol. 697. New York: Springer; 2011. p. 1\u20138."},{"key":"888_CR69","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","volume":"59","author":"F Martin\u00f3n-Torres","year":"2016","unstructured":"Martin\u00f3n-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59:S12\u201320.","journal-title":"J Adolesc Health"},{"key":"888_CR70","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1016\/j.vaccine.2017.09.048","volume":"35","author":"BD Gessner","year":"2017","unstructured":"Gessner BD, Kaslow D, Louis J, et al. Estimating the full public health value of vaccination. Vaccine. 2017;35:6255\u201363.","journal-title":"Vaccine"},{"key":"888_CR71","doi-asserted-by":"publisher","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","volume":"35","author":"DE Bloom","year":"2017","unstructured":"Bloom DE, Brenzel L, Cadarette D, Sullivan J. Moving beyond traditional valuation of vaccination: needs and opportunities. Vaccine. 2017;35:A29\u201335.","journal-title":"Vaccine"},{"key":"888_CR72","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40258-021-00683-z","volume":"20","author":"E Bell","year":"2022","unstructured":"Bell E, Neri M, Steuten L. Towards a broader assessment of value in vaccines: the BRAVE way forward. Appl Health Econ Health Policy. 2022;20:105\u201317.","journal-title":"Appl Health Econ Health Policy"},{"key":"888_CR73","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2105\/AJPH.2020.306114","volume":"111","author":"DE Bloom","year":"2021","unstructured":"Bloom DE, Cadarette D, Ferranna M. The societal value of vaccination in the age of COVID-19. Am J Public Health. 2021;111:1049\u201354.","journal-title":"Am J Public Health"},{"key":"888_CR74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12916-015-0446-9","volume":"13","author":"M Jit","year":"2015","unstructured":"Jit M, Hutubessy R, Png ME, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209.","journal-title":"BMC Med"},{"key":"888_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2345","volume":"10","author":"DE Bloom","year":"2018","unstructured":"Bloom DE, Fan VY, Sevilla JP. The broad socioeconomic benefits of vaccination. Sci Transl Med. 2018;10:eaaj2345.","journal-title":"Sci Transl Med"},{"key":"888_CR76","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15585\/mmwr.mm7035a1","volume":"70","author":"C Pingali","year":"2021","unstructured":"Pingali C, Yankey D, Elam-Evans LD, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:1183\u201390.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"888_CR77","unstructured":"Bart SM, Eberhart M, Feemster K. Impact of a Category B recommendation: meningococcal B (MenB) vaccine uptake among adolescents in Philadelphia County. Presented at: Pediatric Academic Societies, May 5\u20138, 2018; Toronto, ON, Canada."},{"key":"888_CR78","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0140-6736(21)00242-7","volume":"397","author":"Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members","year":"2021","unstructured":"Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet. 2021;397:562\u20134.","journal-title":"Lancet"},{"key":"888_CR79","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.vaccine.2017.12.029","volume":"36","author":"M Teresa Aguado","year":"2018","unstructured":"Teresa Aguado M, Barratt J, Beard JR, et al. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22\u201323 March 2017. Vaccine. 2018;36:921\u201331.","journal-title":"Vaccine"},{"key":"888_CR80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1377\/hlthaff.2022.00343","volume":"42","author":"S Sriudomporn","year":"2023","unstructured":"Sriudomporn S, Sim SY, Mak J, Brenzel L, Patenaude BN. Financing and funding gap for 16 vaccines across 94 low- and middle-income countries, 2011\u201330. Health Aff (Millwood). 2023;42:94\u2013104.","journal-title":"Health Aff (Millwood)"},{"key":"888_CR81","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1473-3099(20)30265-6","volume":"20","author":"T Ducomble","year":"2020","unstructured":"Ducomble T, Gignoux E. Learning from a massive epidemic: measles in DRC. Lancet Infect Dis. 2020;20:542.","journal-title":"Lancet Infect Dis"},{"key":"888_CR82","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jval.2019.04.002","volume":"22","author":"SY Sim","year":"2019","unstructured":"Sim SY, Jit M, Constenla D, Peters DH, Hutubessy RCW. A scoping review of investment cases for vaccines and immunization programs. Value Health. 2019;22:942\u201352.","journal-title":"Value Health"},{"key":"888_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239926","volume":"15","author":"GS Chung","year":"2020","unstructured":"Chung GS, Hutton DW. Epidemiological impact and cost-effectiveness of universal meningitis B vaccination among college students prior to college entry. PLoS ONE. 2020;15:e0239926.","journal-title":"PLoS ONE"},{"key":"888_CR84","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","volume":"36","author":"B Wang","year":"2018","unstructured":"Wang B, Santoreneos R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. Pharmacoeconomics. 2018;36:1201\u201322.","journal-title":"Pharmacoeconomics"},{"key":"888_CR85","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/infdis\/jiaa183","volume":"222","author":"B Ackerson","year":"2020","unstructured":"Ackerson B, An J, Sy LS, et al. Cost of hospitalization associated with respiratory syncytial virus infection versus influenza infection in hospitalized older adults. J Infect Dis. 2020;222:962\u20136.","journal-title":"J Infect Dis"},{"key":"888_CR86","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.vaccine.2020.12.080","volume":"39","author":"M Middeldorp","year":"2021","unstructured":"Middeldorp M, van Lier A, van der Maas N, et al. Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020. Vaccine. 2021;39:1039\u201343.","journal-title":"Vaccine"},{"key":"888_CR87","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s41885-020-00071-2","volume":"4","author":"Y Jinjarak","year":"2020","unstructured":"Jinjarak Y, Ahmed R, Nair-Desai S, Xin W, Aizenman J. Accounting for global COVID-19 diffusion patterns, January-April 2020. Econ Disaster Clim Chang. 2020;4:515\u201359.","journal-title":"Econ Disaster Clim Chang"},{"key":"888_CR88","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/1468-0009.12463","volume":"98","author":"N Maani","year":"2020","unstructured":"Maani N, Galea S. COVID-19 and underinvestment in the public health infrastructure of the United States. Milbank Q. 2020;98:250\u20139.","journal-title":"Milbank Q"},{"key":"888_CR89","unstructured":"Sagan A, Webb E, McKee M, et al. Health systems resilience during COVID-19: lessons for building back better [Health Policy Series 56]. World Health Organization; The European Observatory on Health Systems and Policies. Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/348493\/9789289051873-eng.pdf?sequence=2. Accessed 21 Dec 2022."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00888-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T04:50:18Z","timestamp":1703307018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00888-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00888-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marco A.P. Safadi has received research grants and consultancy fees from Pfizer, GlaxoSmithKline, AstraZeneca, Janssen, and Sanofi Pasteur. David M. Salisbury has received consultancy fees from Pfizer, GlaxoSmithKline, AstraZeneca, Janssen, and Sanofi Pasteur. Paolo Bonanni has received research grants and consultancy fees from Pfizer, GlaxoSmithKline, AstraZeneca, Janssen, Sanofi Pasteur, MSD, Seqirus, and Moderna. Federico Martin\u00f3n-Torres has received honoraria from GSK group of companies, Pfizer Inc, Sanofi, MSD, Seqirus, Biofabri, and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. He has also acted as principal investigator in randomized controlled trials of the aforementioned companies and Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid to his institution. Peter C. Richmond\u2019s institution has received research grants and consultancy fees for participation in scientific advisory boards from Pfizer, GlaxoSmithKline, Sanofi, and Janssen. Katharina Schley, Apostolos Charos, Paul Balmer, and Jamie Findlow are employees of Pfizer and may hold stock or stock options. David E. Bloom has worked on research grants or received travel support or honoraria from Pfizer, Merck, GSK, Moderna, Bavarian Nordic, Janssen, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new data from studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}